Evaluation of essential oils and prebiotics for newborn dairy calves.

A blend of essential oils (EO; carvacrol, caryophyllene, -cymene, cineole, terpinene, and thymol) and prebiotics (arabinogalactans; Stay Strong; Ralco, Inc., Marshall, MN) was designed to promote immunity and stimulate appetite to diminish health challenges and stresses experienced by newborn calves. It was hypothesized that calves supplemented with the medium dose (2.5 g/feeding) of the commercial EO would demonstrate the optimal response. The study objective was to determine the optimal feeding rate of EO when added to a milk replacer (MR) compared with feeding a control or a yeast cell wall additive (YCW). One hundred Holstein calves from a commercial dairy farm were blocked by birth date and randomly assigned to 1 of 5 treatments. Treatments were a control (CON), a 24:20% CP:fat (as-fed basis) MR (24:20 MR) without EO; EO mixed into the 24:20 MR at a rate of 1.25 g/feeding (EO-0.5), EO mixed into the 24:20 MR at a rate of 2.5 g/feeding (EO-1.0), or EO mixed into the 24:20 MR at a rate of 3.75 g/feeding (EO-1.5); or 24:20 MR with YCW mixed in at a rate of 2 g/calf at each feeding. The 24:20 MR was fed in a bucket 2 times/d at a rate of 0.28 kg/calf daily for 14 d, which was increased to 0.43 kg/calf at 2 times/d until d 35 and then reduced to 1 time/d at d 36 to facilitate weaning at d 42. Decoquinate was added to the MR at 41.6 mg/kg for coccidiosis control. Calves were housed in individual hutches bedded with straw with ad libitum access to a 20% CP pelleted calf starter and water. All data were analyzed using PROC MIXED as a completely random design. Calves fed EO-0.5 demonstrated greater ( < 0.05) ADG (0.65, 0.71, 0.64, 0.64, and 0.63 kg/d for the CON, EO-0.5, EO-1.0, EO-1.5, and YCW, respectively) through d 56 compared with calves fed EO-1.0 and YCW and tended ( < 0.10) to have greater ADG than calves fed the CON and EO-1.5. Total BW gains were greater ( < 0.05) for calves fed EO-0.5 compared with calves fed EO-1.0 and YCW, with calves fed the CON and EO-1.5 being intermediate and similar. Body length and wither height gains (final - initial) were greater ( < 0.05) for calves fed EO-0.5 compared with calves fed the other treatments. Hip width gains were similar ( < 0.10) among treatments. Hip height gains were increased ( < 0.05) for calves fed EO-0.5 compared with calves fed the CON, EO-1.0, EO-1.5, and YCW. These results demonstrate that supplementing EO-0.5 (1.25 g/calf daily) in a 24:20 MR may be the optimal feeding rate to enhance growth rates compared with feeding a 24:20 MR and a 24:20 MR containing YCW or other inclusion rates of EO.

Fecal carriage of extended-spectrum ß-lactamase- and carbapenemase-producing Enterobacteriaceae in Egyptian patients with community-onset gastrointestinal complaints: a hospital -based cross-sectional study.

OBJECTIVES: The aim of this study was to determine the prevalence of extended-spectrum ß-lactamase (ESBL) and carbapenemase production among Enterobacteriaceae isolated from ambulatory patients with gastrointestinal complaints admitted to El-Ahrar General Hospital, Zagazig, Egypt in the period between January 2013 and May 2013. METHODS: One hundred and thirteen Enterobacteriaceae isolates were recovered from 100 consecutive Egyptian patients with community-onset gastrointestinal complaints. The fecal samples were plated directly on selective EbSA-ESBL Screening Agar and on MacConkey agar. Isolate identification was performed with matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Screening for ESBLs and carbapenemases production was done by both the automated VITEK®2 system with AST N198 and by disk diffusion method. Real-time PCR and sequencing were used to characterize the resistance genes. Phylogroups of the E. coli isolates were determined by a triplex PCR-based method. RESULTS: Of 100 patients screened for fecal colonization with extended-spectrum ß-lactamase -producing Enterobacteriaceae (ESBL-E) and carbapenemase- producing Enterobacteriaceae (CPE), 68 were colonized with ESBL-E whereas five patients were positive for CPE. One hundred and thirteen Enterobacterceae isolates were recovered from 100 fecal samples, they belonged to E. coli (n = 72), Klebsiella pneumoniae (n = 23), Enterobacter cloacae(n = 3), Salmonella spp. (n = 1) and other Enterobacterceae isolates (n = 14). The blaCTX-M gene was detected in 89.04% (65/73) of the ESBL-producing Enterobacteriaceae, whereas blaSHV and blaTEM were detected in 30.14% (22/73) and 19.18% (14/73) respectively. Three out of 5 carbapenem-resistant isolates harbored New Delhi metallo-beta-lactamase (NDM) and 2 produced Verona integron-encoded metallo- beta -lactamase (VIM). Twenty-two (47.83%) of the ESBL positive isolates were multidrug resistant (MDR). Phylogenetic analysis showed that, of the 51 ESBL-EC isolates, 17 belonged to group B2, 13 to group D, 11 to group A and 10 to group B1. CONCLUSIONS: Nearly two-thirds of the Enterobacteriaceae isolates recovered from feces of ambulatory patients with community-onset gastrointestinal complaints admitted to El-Ahrar General Hospital, Zagazig, Egypt were ESBL producers and one in every 20 patients included in our study was colonized by carbapenemase-producing Enterobacteriaceae. These high colonization rates are worrying, therefore prudent antimicrobial use should be adopted in Egyptian community settings.